{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:28:33Z","timestamp":1769106513061,"version":"3.49.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["heartrhythmopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm O2"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.hroo.2021.09.010","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T03:05:13Z","timestamp":1639710313000},"page":"698-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"PB","title":["Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6054-2720","authenticated-orcid":false,"given":"Samaneh","family":"Salimian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc W.","family":"Deyell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason G.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santabhanu","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel M.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hroo.2021.09.010_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hroo.2021.09.010_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hroo.2021.09.010_bib6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCOUTCOMES.109.880450","article-title":"Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures","volume":"3","author":"Hauptman","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hroo.2021.09.010_bib7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2015.12.046","article-title":"Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation","volume":"67","author":"Roth","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ehjcvp\/pvv016","article-title":"Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival","volume":"1","author":"Witt","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.hroo.2021.09.010_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cardfail.2017.03.001","article-title":"Feasibility and association of neurohumoral blocker up-titration after cardiac resynchronization therapy","volume":"23","author":"Martens","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/00015385.2018.1547469","article-title":"Reduced occurrence of appropriate therapy for ventricular arrhythmias after beta-blocker uptitration following implant of a primary prevention CRT-defibrillator","volume":"75","author":"Martens","year":"2020","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa013168","article-title":"Cardiac resynchronization in chronic heart failure","volume":"346","author":"Abraham","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib12","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":"Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms","volume":"52","author":"Linde","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib15","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.289.20.2685","article-title":"Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial","volume":"289","author":"Young","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.hroo.2021.09.010_bib16","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1161\/01.CIR.0000146336.92331.D1","article-title":"Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure","volume":"110","author":"Abraham","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.09.010_bib17","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0735-1097(03)01042-8","article-title":"Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias","volume":"42","author":"Higgins","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib20","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa0706695","article-title":"Cardiac-resynchronization therapy in heart failure with narrow QRS complexes","volume":"357","author":"Beshai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib21","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1306687","article-title":"Cardiac-resynchronization therapy in heart failure with a narrow QRS complex","volume":"369","author":"Ruschitzka","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib22","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa041489","article-title":"Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction","volume":"351","author":"Hohnloser","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMoa0901889","article-title":"Defibrillator implantation early after myocardial infarction","volume":"361","author":"Steinbeck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.0000012350.99718.AD","article-title":"Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT)","volume":"105","author":"Bansch","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.09.010_bib27","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0735-1097(03)00297-3","article-title":"Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT","volume":"41","author":"Strickberger","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib28","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib29","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib30","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1161\/CIRCULATIONAHA.110.015024","article-title":"Long-term complications related to biventricular defibrillator implantation: rate of surgical revisions and impact on survival: insights from the Italian Clinical Service Database","volume":"123","author":"Landolina","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.09.010_bib31","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.hrthm.2015.02.035","article-title":"The clinical course of patients with implantable cardioverter-defibrillators: extended experience on clinical outcome, device replacements, and device-related complications","volume":"12","author":"van der Heijden","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2021.09.010_bib32","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/pace.12048","article-title":"Outcomes of cardiac resynchronization therapy in the elderly","volume":"36","author":"Killu","year":"2013","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.7326\/M13-1879","article-title":"Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study","volume":"160","author":"Masoudi","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib34","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jacc.2019.09.043","article-title":"Evaluation, management, and outcomes of patients poorly responsive to cardiac resynchronization device therapy","volume":"74","author":"Varma","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.hrthm.2013.11.025","article-title":"Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: fate of \u201cnonresponders\u201d","volume":"11","author":"Rickard","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2021.09.010_bib36","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1253\/circj.CJ-17-0234","article-title":"Survival and heart failure hospitalization in patients with cardiac resynchronization therapy with or without a defibrillator for primary prevention in Japan - analysis of the Japan Cardiac Device Treatment Registry Database","volume":"81","author":"Yokoshiki","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.hroo.2021.09.010_bib37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/clc.23229","article-title":"The VALID-CRT risk score reliably predicts response and outcome of cardiac resynchronization therapy in a real-world population","volume":"42","author":"Bertaglia","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib38","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/ehf2.12740","article-title":"Contemporary use of devices in chronic heart failure in the Netherlands","volume":"7","author":"Raafs","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.5603\/CJ.a2018.0144","article-title":"Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study","volume":"26","author":"Gunten","year":"2019","journal-title":"Cardiol J"},{"key":"10.1016\/j.hroo.2021.09.010_bib40","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.amjcard.2015.02.031","article-title":"Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation","volume":"115","author":"Fauchier","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jacc.2009.11.029","article-title":"Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database","volume":"55","author":"Lee","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/europace\/euu219","article-title":"Efficacy of primary preventive ICD therapy in an unselected population of patients with reduced left ventricular ejection fraction","volume":"17","author":"Sjoblom","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.hroo.2021.09.010_bib43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.hrthm.2013.12.003","article-title":"Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy in a real-world setting: data from the Israeli ICD Registry","volume":"11","author":"Suleiman","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2021.09.010_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/heartjnl-2017-311638","article-title":"Long-term complications, reoperations and survival following cardioverter-defibrillator implant","volume":"104","author":"Hawkins","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.hroo.2021.09.010_bib45","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/europace\/eux166","article-title":"Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD)","volume":"20","author":"Guerra","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.hroo.2021.09.010_bib46","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1161\/CIRCULATIONAHA.119.043012","article-title":"Association between use of primary-prevention implantable cardioverter-defibrillators and mortality in patients with heart failure: a prospective propensity score-matched analysis from the Swedish Heart Failure Registry","volume":"140","author":"Schrage","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.09.010_bib47","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cardfail.2019.08.018","article-title":"Predicting early mortality among implantable defibrillator patients treated with cardiac resynchronization therapy","volume":"25","author":"Theuns","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ejhf.1552","article-title":"Body mass index and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure","volume":"21","author":"Echouffo-Tcheugui","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib49","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00392-019-01553-4","article-title":"Optimizing heart failure treatment following cardiac resynchronization therapy","volume":"109","author":"Jorsal","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2017.03.051","article-title":"Pharmacological treatment changes of chronic heart failure during cardiac resynchronization therapy: a 1-year follow-up study","volume":"238","author":"Rinkuniene","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cardfail.2015.03.006","article-title":"Changes in drug utilization and outcome with cardiac resynchronization therapy: a MADIT-CRT substudy","volume":"21","author":"Penn","year":"2015","journal-title":"J Card Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib52","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.amjcard.2012.01.387","article-title":"Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis","volume":"109","author":"Mantziari","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib53","first-page":"361","article-title":"Adjustments of heart failure medication after implantation of a cardiac resynchronization therapy defibrillator","volume":"103","author":"Hitz","year":"2012","journal-title":"Minerva Med"},{"key":"10.1016\/j.hroo.2021.09.010_bib54","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.amjcard.2004.12.023","article-title":"Use of cardiac resynchronization therapy to optimize beta-blocker therapy in patients with heart failure and prolonged QRS duration","volume":"95","author":"Aranda","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib55","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/clc.20500","article-title":"Beta-blocker utilization and outcomes in patients receiving cardiac resynchronization therapy","volume":"33","author":"Voigt","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib56","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.amjcard.2017.12.013","article-title":"Effect of optimization of medical treatment on long-term survival of patients with heart failure after implantable cardioverter defibrillator and cardiac resynchronization device implantation (from the French National EGB Database)","volume":"121","author":"Massoullie","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib57","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCHEARTFAILURE.109.912683","article-title":"Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF","volume":"3","author":"Heywood","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib58","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1002\/ehf2.12988","article-title":"The role of sacubitril\/valsartan in the management of cardiac resynchronization therapy non-responders: a retrospective analysis","volume":"7","author":"Chun","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib59","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1540-8167.2008.01234.x","article-title":"Mortality of heart failure patients after cardiac resynchronization therapy: identification of predictors","volume":"19","author":"Bai","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib60","first-page":"251","article-title":"Does 'super-responder' patients to cardiac resynchronization therapy still have indications for neuro-hormonal antagonists? Evidence from long-term follow-up in a single center","volume":"16","author":"Hu","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib61","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/europace\/eus152","article-title":"Independent predictors of mortality in patients with advanced heart failure treated by cardiac resynchronization therapy","volume":"14","author":"Kreuz","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.hroo.2021.09.010_bib62","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/eurheartj\/eht514","article-title":"Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy","volume":"35","author":"Schmidt","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.09.010_bib63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/03007995.2019.1670474","article-title":"Adherence to heart failure management medications following cardiac resynchronization therapy","volume":"36","author":"Shah","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.hroo.2021.09.010_bib64","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00380-015-0711-z","article-title":"Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management","volume":"31","author":"Nabeta","year":"2016","journal-title":"Heart Vessels"},{"key":"10.1016\/j.hroo.2021.09.010_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005400","article-title":"Patient, provider, and practice characteristics associated with sacubitril\/valsartan use in the United States","volume":"11","author":"DeVore","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib66","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1540-8167.2008.01333.x","article-title":"Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators","volume":"20","author":"Pietrasik","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.amjcard.2008.02.103","article-title":"Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators","volume":"102","author":"Lai","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1074248409351408","volume":"15","author":"Desai","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.hroo.2021.09.010_bib69","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0002-8703(00)90011-5","article-title":"Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the antiarrhythmics versus implantable defibrillators (AVID) study registry","volume":"139","author":"Pinski","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.hroo.2021.09.010_bib70","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.hrthm.2006.03.027","article-title":"Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators","volume":"3","author":"Tandri","year":"2006","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2021.09.010_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MJT.0b013e3181f2abb3","article-title":"Effect of carvedilol versus metoprolol CR\/XL on mortality in patients with heart failure treated with cardiac resynchronization therapy: a COX multivariate regression analysis","volume":"20","author":"Shen","year":"2013","journal-title":"Am J Ther"},{"key":"10.1016\/j.hroo.2021.09.010_bib72","doi-asserted-by":"crossref","first-page":"f217","DOI":"10.1093\/europace\/euy077","article-title":"Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study","volume":"20","author":"Ruwald","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.hroo.2021.09.010_bib73","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/pace.13326","article-title":"Cardiac resynchronization therapy: a comparative analysis of mortality in African Americans and Caucasians","volume":"41","author":"Fontaine","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib74","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.amjcard.2015.01.020","article-title":"Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study)","volume":"115","author":"AlJaroudi","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib75","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1540-8159.2009.02669.x","article-title":"Left ventricular ejection fraction and absence of ACE inhibitor\/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population","volume":"33","author":"Obeyesekere","year":"2010","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib76","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/CIRCEP.112.971101","article-title":"Predictors of sustained ventricular arrhythmias in cardiac resynchronization therapy","volume":"5","author":"Friedman","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib77","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1540-8159.2009.02566.x","article-title":"Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy","volume":"33","author":"Verma","year":"2010","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib78","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jce.13307","article-title":"Predicting appropriate shocks in patients with heart failure: patient level meta-analysis from SCD-HeFT and MADIT II","volume":"28","author":"Zeitler","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib79","first-page":"14","article-title":"Prevalence and predictors of appropriate implantable cardioverter defibrillator therapy in chronic left ventricular dysfunction patients for primary prevention of sudden cardiac death in Siriraj Hospital","volume":"98","author":"Chichareon","year":"2015","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.hroo.2021.09.010_bib80","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijcard.2017.02.015","article-title":"Effectiveness of a management program for outpatient clinic or remote titration of beta-blockers in CRT patients: The RESTORE study","volume":"236","author":"D'Onofrio","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib81","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2362.2009.02217.x","article-title":"Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment","volume":"39","author":"Adlbrecht","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.hroo.2021.09.010_bib82","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib83","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ehf2.12454","article-title":"Medical therapy doses at hospital discharge in patients with existing and de novo heart failure","volume":"6","author":"Diamant","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib84","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jchf.2020.04.019","article-title":"Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations?","volume":"8","author":"Jarjour","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib85","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib86","first-page":"531","article-title":"CCS\/CHFS Heart Failure Guidelines Update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib87","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/ejhf.1248","article-title":"The misperception of 'stable' heart failure","volume":"20","author":"Pascual-Figal","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib88","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.09.010_bib89","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.hroo.2021.09.010_bib90","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"MOCHA Investigators. Circulation"},{"key":"10.1016\/j.hroo.2021.09.010_bib91","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cardfail.2006.08.213","article-title":"Reducing the risk of sudden death in heart failure with beta-blockers","volume":"12","author":"Adamson","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib92","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00392-018-1378-0","article-title":"Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials","volume":"108","author":"Rossello","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib93","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/ehf2.13313","article-title":"SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis","volume":"8","author":"Yan","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib94","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jchf.2020.06.015","article-title":"Sacubitril\/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: a PARADIGM-HF analysis","volume":"8","author":"Rohde","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hroo.2021.09.010_bib95","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/europace\/eus222","volume":"14","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.hroo.2021.09.010_bib96","first-page":"632","article-title":"A novel approach to medical management of heart failure with reduced ejection fraction","volume":"37","author":"Miller","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib97","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jamacardio.2020.3757","article-title":"Remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction","volume":"5","author":"Desai","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib98","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.120.051863","article-title":"An electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF Trial","volume":"143","author":"Allen","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.09.010_bib99","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced Trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.09.010_bib100","first-page":"737","article-title":"Predictors of super-response to cardiac resynchronization therapy: the significance of heart failure medication, pre-implant left ventricular geometry and high percentage of biventricular pacing","volume":"14","author":"Jin","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.hroo.2021.09.010_bib101","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/1357633X15613701","article-title":"Association between remote implantable cardioverter defibrillator monitoring and beta-blocker utilization: an analysis from the EFFECT study","volume":"22","author":"D'Onofrio","year":"2016","journal-title":"J Telemed Telecare"}],"container-title":["Heart Rhythm O2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501821001926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501821001926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:27:06Z","timestamp":1762993626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666501821001926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2666501821001926"],"URL":"https:\/\/doi.org\/10.1016\/j.hroo.2021.09.010","relation":{},"ISSN":["2666-5018"],"issn-type":[{"value":"2666-5018","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm O2","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hroo.2021.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Heart Rhythm Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}